Overactive bladder (OAB) is a common condition that significantly impairs quality of life. Botulinum toxin injection therapy has recently emerged as an effective treatment option for patients who are refractory to conventional pharmacological therapies. We started intravesical botulinum toxin for patients with overactive bladder from June 2023 at our clinic. We report our initial clinical experience with intravesical botulinum toxin injections for OAB, focusing on efficacy, safety, and short-term outcomes.

We identified 15 (6 male and 9 female) patients with overactive bladder who underwent intravesical botulinum toxin at our clinic from June 2023 to August 2024. We do this treatment with local anesthesia. Their average age was 72.8 (47-85). Preoperative OABSS (overactive bladder symptom score) was 11.8 (7-12). Preoperative median residual volume after urination was 21mm (0-47).

Median OABSS and residual volume was 4.8 (1-9) and 22ml (0-61) on the date of 1 post operative month. OABSS was significantly improved after 1month. And there were no major complications.Moreover, on the date of 3 post operative month, OABSS becomes 4.5(1-8).

Intravesical botulinum toxin injection therapy was performed safely without any severe complications in our initial series. Patients showed a significant improvement in Overactive Bladder Symptom Scores (OABSS), suggesting the efficacy of this treatment for those who are refractory to conventional pharmacological therapy. While short-term outcomes appear promising, the long-term durability of symptom relief and the incidence of delayed adverse events remain unclear. Further accumulation of cases and long-term follow-up are essential to fully assess the therapeutic potential and to identify predictors of response and risk factors for complications.